

REMARKS

The substitute Sequence Listing enclosed herewith has been voluntarily amended to facilitate its administrative processing, and not for reasons related to patentability.

I hereby state that the amendments included in the substitute Sequence Listing are supported in the application, as filed, at least in the original Sequence Listing, for the amendments to SEQ ID NOS:1, 2, 3, 4, 11, 17, 18 and 22. The amendments to <110>, <130>, <140>, <141> and <151> in the Sequence Listing reflect U.S. filing information. Thus, the substitute Sequence Listing does not include new matter.

A copy of the substitute Sequence Listing in computer readable form, along with the required Statement under 37 C.F.R. 1.825(a) and 1.825(b), are filed simultaneously herewith.

Please charge any necessary fee to Deposit Account 04-1928
(E. I. du Pont de Nemours and Company).

In view of the foregoing, allowance of the above-referenced application is respectfully requested.

Respectfully submitted,

Dawn S. Clark

DAWN S. CLARK, PH.D.
AGENT FOR APPLICANTS
REGISTRATION NO. 42,420
TELEPHONE: 302-695-1080
FACSIMILE: 302-695-3125

Dated: May 27, 2004

Enclosures: substitute Sequence Listing